Hepatocyte cell therapy (Heparesc) - Promethera Biosciences

Drug Profile

Hepatocyte cell therapy (Heparesc) - Promethera Biosciences

Alternative Names: Heparesc; HHLivC; Human heterologous liver cells for infusion

Latest Information Update: 05 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Cytonet
  • Developer Cytonet; Promethera Biosciences
  • Class Cell therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Inborn urea cycle disorders; Liver failure
  • New Molecular Entity No

Highest Development Phases

  • Preregistration Inborn urea cycle disorders
  • Phase II/III Liver failure

Most Recent Events

  • 03 Jul 2017 Preregistration for Inborn urea cycle disorders (In children, In infants, In neonates) in Canada prior to July 2017 (IV)
  • 03 Jul 2017 Health Canada accepts New Drug Submission for Hepatocyte cell therapy for Inborn urea cycle disorders for review
  • 09 Jan 2017 Promethera Biosciences and LifeLiver enter into a strategic alliance to jointly develop Heparesc® in South Korea
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top